Suppr超能文献

中国抗击 COVID-19 的治疗策略及针对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的潜在小分子抑制剂。

Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

机构信息

Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, Guangdong Laboratory for Lingnan Modern Agriculture, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.

Guangdong Institute of Analysis (China National Analytical Center, Guangzhou), Guangzhou 510070, China.

出版信息

J Med Chem. 2020 Nov 25;63(22):13205-13227. doi: 10.1021/acs.jmedchem.0c00626. Epub 2020 Sep 11.

Abstract

The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to more than 20 million people infected worldwide with an average mortality rate of 3.6%. This virus poses major challenges to public health, as it not only is highly contagious but also can be transmitted by asymptomatic infected individuals. COVID-19 is clinically difficult to manage due to a lack of specific antiviral drugs or vaccines. In this article, Chinese therapy strategies for treating COVID-19 patients, including current applications of traditional Chinese medicine (TCM), are comprehensively reviewed. Furthermore, 72 small molecules from natural products and TCM with reported antiviral activity against human coronaviruses (CoVs) are identified from published literature, and their potential applications in combating SARS-CoV-2 are discussed. Among these, the clinical efficacies of some accessible drugs such as remdesivir (RDV) and favipiravir (FPV) for COVID-19 are emphatically summarized. We hope this review provides a foundation for managing the worsening pandemic and developing antivirals against SARS-CoV-2.

摘要

由严重急性呼吸系统综合症冠状病毒 2 型(SARS-CoV-2)引起的 2019 年冠状病毒病(COVID-19)已导致全世界超过 2000 万人感染,平均死亡率为 3.6%。该病毒对公共卫生构成重大挑战,因为它不仅具有高度传染性,而且还可以通过无症状感染者传播。由于缺乏特异性抗病毒药物或疫苗,COVID-19 在临床上难以治疗。在本文中,全面综述了中国治疗 COVID-19 患者的治疗策略,包括中药(TCM)的当前应用。此外,从已发表的文献中确定了来自天然产物和 TCM 的 72 种具有抗人类冠状病毒(CoV)活性的小分子,并讨论了它们在对抗 SARS-CoV-2 中的潜在应用。其中,重点总结了瑞德西韦(RDV)和法匹拉韦(FPV)等一些可及药物治疗 COVID-19 的临床疗效。我们希望这篇综述为管理日益恶化的大流行和开发针对 SARS-CoV-2 的抗病毒药物提供了基础。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验